7 results on '"Baird, John H."'
Search Results
2. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist.
- Author
-
Ong, Shin Yeu and Baird, John H.
- Published
- 2023
- Full Text
- View/download PDF
3. An Unusual Cause of Epistaxis: Paranasal Sinus Myeloid Sarcoma.
- Author
-
Dewan, Karuna, Baird, John H., and Shires, Courtney B.
- Subjects
- *
SPHENOID sinus , *PARANASAL sinuses , *NOSEBLEED , *FLUORESCENCE in situ hybridization , *BONE marrow , *CAVERNOUS sinus - Abstract
We report a case of a 65-year-old female who presented with right-sided headaches, blurring of vision in the right eye, cold-induced epistaxis, and facial numbness in the trigeminal nerve distribution. Laboratory studies revealed a significant number of myeloblasts on peripheral smear with granulated cytoplasm, irregular nuclei, and prominent vacuoles. Magnetic resonance imaging (MRI) of the brain demonstrated a T1-enhancing 1.5 cm right-sided dural-based lesion involving the medial sphenoid wing, cavernous sinus, infratemporal fossa, and sphenoid sinus region. An endoscopic biopsy of the lesion within the sphenoid sinus confirmed the diagnosis of myeloid sarcoma, with myeloblasts comprising 30% of cellularity by flow cytometry. A subsequent bone marrow biopsy revealed a hypercellular marrow with 23% blasts by flow cytometry that demonstrated a similar immunophenotypic pattern to those seen in the sinus mass. Fluorescence in situ hybridization (FISH) testing revealed the balanced translocation t(8;21)(q22;q22.1), consistent with a diagnosis of acute myeloid leukemia with RUNX1-RUNX1T1-balanced translocation by WHO 2016 criteria. Myeloid sarcoma represents a rare extramedullary presentation of acute myeloid leukemia (AML), either alone or in conjunction with blood or bone marrow involvement. This case emphasizes the need for a broad differential diagnosis and an aggressive work-up for any unusual paranasal sinus mass. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. The Hemorrhage that Wasn't: Polycythemia Presenting as a Pseudointracranial Hemorrhage in Pedestrian vs Automobile Trauma Alert.
- Author
-
Phillips, Andrew W., Baird, John H., Wentland, Andrew L., Yang, Rachel L., and Massoud, Tarik F.
- Subjects
- *
POLYCYTHEMIA , *MYELOPROLIFERATIVE neoplasms , *POLYCYTHEMIA vera , *HEALTH care teams , *OBSTRUCTIVE lung diseases - Abstract
Introduction: Although polycythemia vera is rarely seen, absolute polycythemia is seen more frequently and can drastically change imagine interpretation when taken out of context of the patient's chief complaint. Case Report: We report the case of a 21-year-old male without any known medical history who presented as a trauma patient initially diagnosed with acute subarachnoid and subdural hemorrhages. Further examination of the imaging and later serum laboratory findings demonstrated a primary diagnosis of absolute polycythemia, which was an incidental diagnosis that resulted in the patient's care team and disposition being changed. Conclusion: Absolute polycythemia is not uncommon, and its causes vary from congenital and myeloproliferative disorders to chronic obstructive pulmonary disease and sleep apnea. It can cause pseudoenhancement in noncontrast computed tomography (CT) scans because of the increased protein level in the blood, and emergency physicians should consider all differential diagnoses of pseudoenhancement. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide.
- Author
-
Baird, John H., Minniti, Caterina P., Lee, Jung‐Min, Tian, Xin, Wu, Colin, Jackson, Mary, Alam, Shoaib, Taylor, James G., and Kato, Gregory J.
- Subjects
- *
MYELOID leukemia , *SICKLE cell anemia treatment , *HYDROXYUREA , *MYELOPROLIFERATIVE neoplasms , *HEMOGLOBINS , *LEUCOCYTE disorders , *THERAPEUTICS - Abstract
Hydroxycarbamide therapy has been associated with significant oscillations in peripheral blood counts from myeloid, lymphoid and erythroid lineages in patients with polycythaemia vera and chronic myeloid leukaemia. We retrospectively evaluated serial blood counts over an 8-year period from 44 adult patients with sickle cell disease receiving hydroxycarbamide. Platelet counts, leucocyte counts, haemoglobin values and reticulocyte counts, apportioned by hydroxycarbamide status, were analysed using a Lomb-Scargle periodogram algorithm. Significant periodicities were present in one or more counts in 38 patients receiving hydroxycarbamide for a mean duration of 4·81 years. Platelet and leucocyte counts oscillated in 56·8% and 52·3% of patients, respectively. These oscillations generally became detectable within days of initiating therapy. During hydroxycarbamide therapy, the predominant periods of oscillation were 27 ± 1 d for platelet counts and 15 ± 1 d for leucocyte counts. Despite an absolute decrease in leucocyte and platelet counts during hydroxycarbamide treatment, the amplitudes between nadirs and zeniths remained similar regardless of exposure. Our observations appear consistent with previously proposed models of cyclic haematopoiesis, and document that hydroxycarbamide-induced oscillations in blood counts are innocuous phenomena not limited to myeloproliferative disorders as described previously. We speculate the known cell cycle inhibitory properties of hydroxycarbamide may accentuate otherwise latent constitutive oscillatory haematopoiesis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma.
- Author
-
Ladbury, Colton, Dandapani, Savita, Hao, Claire, Fabros, Mildred, Amini, Arya, Sampath, Sagus, Glaser, Scott, Sokolov, Karen, Yeh, Jekwon, Baird, John H., Kambhampati, Swetha, Herrera, Alex, Mei, Matthew, Nikolaenko, Liana, Shouse, Geoffrey, and Budde, Lihua E.
- Subjects
- *
PATIENT aftercare , *TIME , *B cell lymphoma , *CANCER relapse , *CELL receptors , *TREATMENT effectiveness , *DESCRIPTIVE statistics , *T cells , *ADVERSE health care events , *PROGRESSION-free survival , *OVERALL survival - Abstract
Simple Summary: Bridging therapy (BT) in the form of systemic therapy (ST), radiation therapy (RT), or combined-modality therapy (CMT) is increasingly being utilized prior to chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL). Prior institutional experiences with BT, and RT in particular, suggest it does not lead to increased toxicity or compromise outcomes. Further investigation of the optimal use of BT is warranted. In this research, we sought to evaluate the impact of BT in a large institutional cohort of patients who received commercial CAR T-cell therapy for LBCL, specifically examining the effect of BT modality and disease burden on outcomes. Here, we report the long-term outcomes of our CAR T cohort. The patients with limited disease treated with RT had favorable outcomes. Prospective studies are warranted to better characterize the optimal management of patients with relapsed/refractory LBCL who are planning to undergo CAR T-cell therapy to optimize treatment. Background: Bridging therapy (BT) with systemic therapy (ST), radiation therapy (RT), or combined-modality therapy (CMT) is increasingly being utilized prior to chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL). We report the long-term outcomes of the patients who received commercial CAR T-cell therapy with or without BT. Methods: The patients with LBCL who underwent infusion of a commercial CD19 CAR T product were eligible. The radiation was stratified as comprehensive or focal. The efficacy outcomes and toxicity were analyzed. Results: In total, 156 patients were included and, of them, 52.5% of the patients received BT. The median progression-free survival (PFS) was 0.65 years in the BT cohort compared to 1.45 years in the non-BT cohort. The median overall survival (OS) was 3.16 years in the BT cohort and was not reached in the non-BT cohort. The patients who received comprehensive radiation (versus focal) had significantly improved PFS and OS, achieving a 1-year PFS of 100% vs. 9.1% and 1-year OS of 100% vs. 45.5%. There was no difference in the severe toxicity between any of the nonbridging or BT cohorts. Conclusions: BT did not appear to compromise outcomes with respect to response rates, disease control, survival, and toxicity. The patients with limited disease treated with RT had favorable outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
- Author
-
Sworder, Brian J., Kurtz, David M., Alig, Stefan K., Frank, Matthew J., Shukla, Navika, Garofalo, Andrea, Macaulay, Charles W., Shahrokh Esfahani, Mohammad, Olsen, Mari N., Hamilton, James, Hosoya, Hitomi, Hamilton, Mark, Spiegel, Jay Y., Baird, John H., Sugio, Takeshi, Carleton, Mia, Craig, Alexander F.M., Younes, Sheren F., Sahaf, Bita, and Sheybani, Natasha D.
- Subjects
- *
T cells , *B cells , *CIRCULATING tumor DNA , *B cell lymphoma , *T cell receptors , *CELL-free DNA , *CD19 antigen - Abstract
Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19 chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of resistance, we profiled over 700 longitudinal specimens from two independent cohorts (n = 65 and n = 73) of r/rLBCL patients treated with axicabtagene ciloleucel. A method for simultaneous profiling of circulating tumor DNA (ctDNA), cell-free CAR19 (cfCAR19) retroviral fragments, and cell-free T cell receptor rearrangements (cfTCR) enabled integration of tumor and both engineered and non-engineered T cell effector-mediated factors for assessing treatment failure and predicting outcomes. Alterations in multiple classes of genes are associated with resistance, including B cell identity (PAX5 and IRF8), immune checkpoints (CD274), and those affecting the microenvironment (TMEM30A). Somatic tumor alterations affect CAR19 therapy at multiple levels, including CAR19 T cell expansion, persistence, and tumor microenvironment. Further, CAR19 T cells play a reciprocal role in shaping tumor genotype and phenotype. We envision these findings will facilitate improved chimeric antigen receptor (CAR) T cells and personalized therapeutic approaches. [Display omitted] • Tumors and CAR T cell effectors can be simultaneously profiled using cell-free DNA • Alterations in multiple classes of genes influence outcomes after CAR19 therapy • Tumor genotype and phenotype influence CAR19 T cell expansion, and vice versa • A multivariable model incorporating tumor and effector features predicts outcomes Sworder et al. develop and apply a tool to simultaneously profile tumor and effector-mediated determinants of resistance to anti-CD19 CAR T cells using cell-free DNA. The authors profile two independent cohorts of patients with relapsed/refractory large B cell lymphoma and identify genomic alterations, molecular thresholds, and microenvironmental changes associated with resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.